Get the Stockscreener App
328.18
0.16%
0.51
After Hours:
328.18
Natera Inc stock is traded at $328.18, with a volume of 968.03K.
It is up +0.16% in the last 24 hours and up +19.26% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$327.67
Open:
$323.92
24h Volume:
968.03K
Relative Volume:
0.71
Market Cap:
$47.31B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-199.96
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+0.59%
1M Performance:
+19.26%
6M Performance:
+61.64%
1Y Performance:
+97.03%
1-Day Range:
$323.42
$329.05
1-Week Range:
$316.00
$332.00
52-Week Range:
$157.43
$343.18
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Net debt of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - TradingView
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Diluted earnings per share (diluted EPS) of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - TradingView
Gross profit of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) Revenue Breakdown – BCBA:NTRA.CI - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA - TradingView
Guggenheim maintains Buy on Natera, raises target to $290 - scanx.trade
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAC - TradingView
The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership - simplywall.st
Natera CEO Steven Chapman sells $545k in NTRA shares By Investing.com - Investing.com South Africa
Natera president Solomon Moshkevich sells over $5.9m in shares By Investing.com - Investing.com South Africa
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Natera stock trades near 52-week high as guidance and regulatory wins support growth - AD HOC NEWS
Natera Inc (NTRA) CEO and President Steven Chapman Sells 1,698 S - GuruFocus
Natera president Solomon Moshkevich sells over $5.9m in shares - Investing.com
Natera CEO Steven Chapman sells $545k in NTRA shares - Investing.com
Natera (NASDAQ: NTRA) exec sells shares for taxes and under pre-set plan - Stock Titan
Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones! - Smartkarma
Natera: $8.25M Prenatal Test Class Action Settlement Approved - Wansom AI
After recent stock sales, Natera (NASDAQ: NTRA) exec files notice to sell more shares - Stock Titan
Planned stock sale by Natera (NTRA) holder follows 41,124-share trade - Stock Titan
Natera (NASDAQ: NTRA) executive plans nearly $1M share sale after $2M in recent trades - Stock Titan
NTRA Looks 47.2% Overvalued on GF Value™ - GuruFocus
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma - FinancialContent
Pretax income of Natera, Inc. – LSX:A14VPJ - TradingView
Natera, Inc. (NTRA) Stock Analysis: A Healthcare Powerhouse with a 3.21% Upside Potential - DirectorsTalk Interviews
Natera Stock (NTRA) Opinions on Recent Price Surge - moomoo.com
Natera president John Fesko sells $2.1m in company stock By Investing.com - Investing.com Nigeria
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera - Eastern Progress
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer - Yahoo Finance
Natera partners with Angiex for cancer drug trial testing - Investing.com
Is Natera’s (NTRA) Kupando MRD Deal a Stepping Stone in Its Oncology Strategy? - simplywall.st
Natera: The Growth May Not Justify Current Levels - Seeking Alpha
Natera, Inc. (NTRA) Stock Analysis: A Healthcare Pioneer with 37.7% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Natera’s Oncology Push Has Wall Street Paying Up - Finimize
Natera Inc. Earnings Call Highlights Rapid Growth - TipRanks
Natera raises FY26 guidance to $2.85B-$2.91B after record Q2 volume - scanx.trade
Silvant Capital Management LLC Takes $12.32 Million Position in Natera, Inc. $NTRA - MarketBeat
Virtus Advisers LLC Takes $1.01 Million Position in Natera, Inc. $NTRA - MarketBeat
Ninepoint Partners LP Purchases New Position in Natera, Inc. $NTRA - MarketBeat
D L Carlson Investment Group Inc. Makes New $3.49 Million Investment in Natera, Inc. $NTRA - MarketBeat
Deutsche Bank AG Purchases Shares of 320,037 Natera, Inc. $NTRA - MarketBeat
Danske Bank A S Makes New Investment in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. (NASDAQ:NTRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Natera (NTRA) Earnings Snapshot: Profit Per Share Surpasses Its Benchmark; Price Reaction: The Stock Loses 0.07% at the CloseEPS Guidance Update - vinanet.vn
Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story? - AOL.com
Natera stock reaches all-time high at 326.26 USD By Investing.com - Investing.com Australia
Natera (NASDAQ:NTRA) Reaches New 1-Year HighTime to Buy? - MarketBeat
Natera stock reaches all-time high at 326.26 USD - Investing.com
Natera (NTRA) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; Latest Reaction - vinanet.vn
Mitsubishi UFJ Asset Management Co. Ltd. Takes $50.42 Million Position in Natera, Inc. $NTRA - MarketBeat
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Sep 01 '26 |
Sale |
320.73 |
3,000 |
962,194 |
126,019 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Sep 01 '26 |
Sale |
320.99 |
1,698 |
545,041 |
98,199 |
1.42%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):